Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2015 Jul 16;373(3):288-90.
doi: 10.1056/NEJMc1505197.

Anti-PD-1-Related Pneumonitis during Cancer Immunotherapy

Mizuki Nishino  1 , Lynette M Sholl, F Stephen Hodi, Hiroto Hatabu, Nikhil H Ramaiya
Affiliations
Case Reports

Anti-PD-1-Related Pneumonitis during Cancer Immunotherapy

Mizuki Nishino et al. N Engl J Med. .
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1. CT of the Chest Performed in Three Patients with Pneumonitis Associated with the Use of Anti– Programmed Cell Death 1 Antibodies
In Patient 1, a 70-year-old man with advanced melanoma who was treated in a trial of nivolumab given sequentially with ipilimumab, chest CT at 22 weeks of therapy revealed consolidation in the bilateral lower lobes with reticular and ground-glass opacities (Panel A, arrows). Two weeks later, the findings significantly progressed (Panel B, asterisks) and involved all lobes, with decreased lung volumes and pleural effusion. In Patient 2, a 38-year-old woman with advanced melanoma who was treated with nivolumab, chest CT at 15 weeks of therapy revealed diffuse ground-glass opacities, reticular opacities, consolidations, traction bronchiectasis, and areas of centrilobular nodularity (Panel C) involving all lobes and more than 50% of all lung zones, with decreased lung volumes. In Patient 3, a 58-year-old man with advanced melanoma who was treated with nivolumab, chest CT at 7 weeks of therapy revealed bilateral ground-glass opacities, reticular opacities, and small areas of consolidation in predominantly lower and peripheral distribution (Panel D, arrows), indicative of a pattern of nonspecific interstitial pneumonia.
See this image and copyright information in PMC

References

    1. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti–PD-1 antibody in cancer. N Engl J Med. 2012;366:2443–54. - PMC - PubMed
    1. Rizvi NA, Mazières J, Planchard D, et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol. 2015;16:257–65. - PMC - PubMed
    1. Topalian SL, Sznol M, McDermott DF, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol. 2014;32:1020–30. - PMC - PubMed
    1. Robert C, Ribas A, Wolchok JD, et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumabrefractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet. 2014;384:1109–17. - PubMed
    1. American Thoracic Society, European Respiratory Society. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias: this joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med. 2002;165:277–304. - PubMed